⚡ Quick Start — If You Read Nothing Else

The 10 most important things to know about geographic atrophy right now.

Geographic atrophy (GA) is the advanced, late form of “dry” age-related macular degeneration (AMD). Over years, patches of the light-sensing retina and its support layer slowly die, creating blind spots that grow and eventually merge near the center of vision.
For the first time in history, there are FDA-approved treatments. Two eye-injection medicines — pegcetacoplan (Syfovre) and avacincaptad pegol (Izervay) — were approved in 2023. They are the first drugs ever shown to change the course of GA.
These drugs slow GA down — they do not reverse it or restore lost vision. The goal is to protect the sight you still have for as long as possible. Understanding this honestly is the single most important step in deciding about treatment.
The benefit grows the longer you stay on treatment. Five-year data for Syfovre show progression delayed by about 1.5 years; long-term Izervay data show the gap vs. no treatment widening to roughly 40% by 3.5 years.
Starting early — before the atrophy reaches the very center (the fovea) — gives you the most to protect. If your GA is still away from the center, you and your retina specialist have an important window.
The two drugs have different safety profiles. Syfovre carries an FDA warning (added December 2024) about a rare but serious inflammation of the retinal blood vessels (retinal vasculitis), most often after the first injection. Izervay has not shown these vasculitis cases in long-term studies. Discuss this trade-off with your doctor.
AREDS2 vitamins are still recommended — but they are prevention, not a GA treatment. The AREDS2 supplement formula lowers the chance of dry AMD getting worse. It does not shrink or stop an atrophy patch that has already formed.
You need a retina specialist, and you need regular imaging. Special scans — OCT and fundus autofluorescence (FAF) — map your atrophy and track how fast it is growing. They also catch a sudden switch to “wet” AMD, which needs different, urgent treatment.
Low-vision rehabilitation should start early, not after you go blind. Magnifiers, lighting, contrast, screen readers, and eccentric-viewing training can keep you reading, cooking, and living independently. Ask for a referral now.
You will not go completely blind from GA. GA almost always spares your side (peripheral) vision, so you keep the ability to move around and orient yourself even in advanced disease. The loss is concentrated in detailed central vision.
Report sudden vision change, eye pain, redness, or new floaters immediately. After any injection, these can be the first sign of inflammation, vasculitis, or infection. A sudden new blur or wavy distortion can mean a conversion to wet AMD. Do not wait.

▼ Collapse

Understanding Geographic Atrophy

If you or someone you love has just been told they have geographic atrophy, the name itself can be confusing — it has nothing to do with geography in the usual sense. It refers to the way the damaged areas of the retina look on an eye scan: sharply outlined patches, like islands or countries on a map. This guide is here to explain what GA is, what the new treatments can and cannot do, and what questions to ask, so you can make confident decisions with your eye doctor.

Geographic atrophy is the advanced (late) stage of “dry” age-related macular degeneration. The macula is the small central part of the retina responsible for sharp, straight-ahead vision — the vision you use to read, recognize faces, drive, and see fine detail. In GA, the support layer beneath the retina (the retinal pigment epithelium, or RPE) and the light-sensing cells above it gradually break down in patches. Those patches are called atrophy, and over time they enlarge and can join together.

There is genuine, evidence-based reason for hope. For decades there was nothing doctors could offer to change the course of GA. That changed in 2023, when two medicines became the first treatments ever approved to slow it. Real-world experience now spans hundreds of thousands of injections, and the research pipeline — gene therapies, cell transplants, and new complement drugs — is the most active it has ever been. A diagnosis of GA today is very different from a diagnosis even three years ago.

Dry AMD, geographic atrophy, and wet AMD — how they fit together

AMD comes in two broad forms, and the words are easy to mix up:

Dry AMD is by far the most common (about 85–90% of AMD). It begins with yellowish deposits under the retina called drusen and changes in the pigment layer. Most people with early or intermediate dry AMD see reasonably well for years.
Geographic atrophy is what dry AMD becomes when it advances: actual loss (atrophy) of retinal tissue in defined patches. This is the late, sight-threatening form of dry AMD.
Wet AMD (also called neovascular AMD) is different: abnormal, leaky blood vessels grow under the retina. It can cause sudden vision loss but is treated with a separate class of injections (anti-VEGF drugs such as aflibercept, ranibizumab, faricimab, or bevacizumab). Importantly, a person with GA can also develop wet AMD — which is one reason regular monitoring matters.

One way to picture it: dry AMD is a slow wearing-down of the macula; geographic atrophy is the patches where the tissue has actually worn through; and wet AMD is a separate “plumbing” problem of leaky vessels that can occur on top of either.

What GA does to vision

GA usually progresses slowly and painlessly, which is why it can go unnoticed at first. Because the atrophy often starts around the very center rather than dead-center, many people keep good reading vision for a surprisingly long time before noticing problems — a feature doctors call “foveal sparing.” As the patches grow toward and into the center (the fovea), people typically notice:

Difficulty reading small print, even with good light, or letters that seem to fade, smear, or disappear in the middle of a word.
A blurred, missing, or dark patch in the center of vision (a scotoma) that may make faces hard to recognize while the rest of the scene stays visible.
Needing much brighter light than before, and trouble adjusting when moving between bright and dim rooms (slow “dark adaptation”).
Reduced ability to see contrast — for example, a white cup on a light tablecloth, or steps that are all the same color.
Trouble seeing in dim restaurants or at dusk, often one of the earliest day-to-day complaints.

GA almost always spares the peripheral (side) vision, so it does not cause total blindness. People with advanced GA can usually still walk around and orient themselves — the loss is concentrated in the detailed central vision. This is important to hold onto: even “advanced” GA leaves you with usable vision that rehabilitation can help you make the most of.

How GA tends to progress over time

Every person is different, but some general patterns help set expectations:

GA enlarges at a fairly steady pace for a given person — often measured by doctors as roughly 1–3 square millimeters of growth per year, though this varies widely.
It is frequently bilateral over time: if one eye has GA, the other is at higher risk.
Lesions that start away from the center (extrafoveal) eventually tend to grow toward it; vision changes most when the fovea becomes involved.
Certain patterns on imaging predict faster growth (your doctor can tell you whether yours appears fast- or slow-growing).

Your body has an ancient part of the immune system called the complement system — a cascade of proteins that normally helps clear debris and fight infection. In AMD, this system becomes overactive in the retina and starts damaging the very cells it should protect. Over time, this chronic, low-grade “friendly fire” helps drive the cell death that creates atrophy.

This discovery is the reason the new treatments exist. Both approved drugs are complement inhibitors — they turn down specific steps in that cascade (Syfovre blocks a protein called C3; Izervay blocks C5, a step further along). By dialing back the overactivity, they slow the rate at which atrophy spreads. They cannot revive cells that are already gone, which is why they slow rather than reverse the disease. Researchers are now testing whether blocking other steps in the cascade (such as C1q, the start of one branch) or even replacing lost cells can do better.

How GA affects daily life

Because GA targets the central vision you rely on for detail, its effects are very specific — and understanding them helps you and your family prepare. People commonly find that reading small print, threading a needle, reading a thermostat, or recognizing a face across a room becomes harder, while getting around a familiar room or walking outdoors stays manageable thanks to preserved side vision. Glare and dim light are frequent challenges, so a brightly lit restaurant menu or a dusk drive can be far harder than the eye-chart number suggests. Many people adapt remarkably well with the right lighting, magnification, and habits — which is why the “Living Well” section of this guide matters as much as the treatment section. The goal throughout is the same: protect remaining vision medically where it makes sense, and maximize what you can do with the vision you have.

Who develops geographic atrophy

GA affects roughly 1 million people in the United States and more than 8 million worldwide, with about 160,000 new U.S. cases a year. AMD is the leading cause of irreversible central vision loss in older adults in high-income countries. The biggest risk factors are:

Age — risk rises steeply after 75.
Smoking — the strongest factor you can actually change; it roughly doubles AMD risk and speeds progression.
Family history and genetics — variants in genes such as CFH and ARMS2 raise risk (more in the diagnosis section).
Having advanced AMD in the other eye, lighter eye/skin pigmentation, cardiovascular disease, and a diet low in leafy greens and fish.

Common questions, honest answers

These are the questions people most often ask after a GA diagnosis. The answers are general; your own situation may differ, so use them as a starting point for conversation with your retina specialist.

“Will I go completely blind?” Almost certainly not from GA alone. GA attacks central, detailed vision but spares the side vision you use to move about, so people keep useful navigational vision even in advanced disease. “Legally blind” (a measure of central sharpness) is not the same as seeing nothing.
“Can diet, vitamins, or supplements cure it?” No. AREDS2 vitamins and a healthy diet can lower the chance of dry AMD getting worse, but nothing currently available reverses atrophy that has already formed. Be cautious of products marketed as cures.
“If the atrophy is already in my center, is treatment pointless?” Not necessarily — but the benefit may be smaller, and it is very reasonable to weigh the burden and risks of injections against what there is to protect. This is exactly the kind of decision to make together with your doctor, and choosing low-vision support instead of injections can be a perfectly sound choice.
“Is GA hereditary — should my children worry?” Genes contribute, but GA is not a simple inherited disease. The best advice for relatives is practical: don’t smoke, eat well, protect eyes from the sun, and get regular dilated eye exams as they age. Genetic testing is generally not necessary.
“I only have it in one eye — what now?” Protect and monitor the good eye carefully (it is at higher risk over time), use your Amsler grid, and ask about treating the affected eye. Many people function very well with one strong eye.
“How fast will I lose vision?” GA usually progresses gradually over years, not weeks. Your doctor can estimate your pace from how your scans change over time. Sudden changes are unusual and should prompt a call — they may signal wet AMD rather than GA itself.
“Should I stop driving?” Not automatically — it depends on your remaining central vision and local rules. Ask for an honest assessment and, if needed, a formal driving evaluation, and plan alternatives before it becomes unsafe.

If you have been diagnosed with geographic atrophy in one eye, your other eye deserves close and active attention. The risk of AMD progressing to GA in the second eye is substantially higher than in someone who has never had AMD, and many people eventually develop GA in both eyes over years. Understanding this — and what to do about it — is as important as managing the eye already affected.

What the risk actually is: Having GA in one eye is one of the strongest predictors of GA developing in the other eye over time. Studies suggest that within 5 years of GA appearing in one eye, there is a meaningful risk of the fellow eye also progressing to the atrophic stage, though the exact number varies widely depending on the stage of AMD already present in the second eye, genetic factors, and lifestyle. If the second eye has intermediate AMD (large drusen, pigment changes), the progression risk is higher than if it has only early AMD.

Monitor the second eye closely: Your retina specialist will image and examine both eyes at every visit, but the second eye warrants particular attention if it has not yet reached GA. FAF imaging of the second eye establishes a baseline for any early atrophy and tracks drusen patterns. OCT assesses drusen size, pigment epithelial detachments, and any early atrophy. OCTA screens for the wet AMD conversion risk that exists in the second eye independently.

Home monitoring matters double: Use your Amsler grid for both eyes at every daily check. Because your brain tends to compensate when one eye has reduced central vision (the better eye “takes over”), you may not notice early changes in the second eye if you are only testing with both eyes open. Always test each eye separately, one at a time, covering the other completely.

AREDS2 supplements protect the second eye: One of the clearest use cases for the AREDS2 vitamin formula is reducing the risk of the second eye — currently at intermediate AMD — advancing to late-stage AMD (either GA or wet AMD). The clinical trial that proved AREDS2 works enrolled people at exactly this risk profile: AMD in one or both eyes, at risk of progression. Take the formula consistently, as the benefit is about ongoing risk reduction, not a one-time protection.

If the second eye eventually needs treatment too: The complement-inhibitor injections can be given in both eyes, though this doubles the injection burden, visit frequency, cost, and risk exposure. Many retina specialists treat the eye with the most to protect first and reassess the second eye based on its trajectory. This is a decision to make together with your specialist based on each eye’s status. The key point: the conversation about the second eye should happen proactively and early, not only after GA has already established itself there.

Almost everyone over 60 notices that vision is not quite what it was at 30. Reading glasses become necessary, adjusting from bright outdoor light to a dim room takes longer, and glare from headlights at night becomes more bothersome. These changes are normal and expected. Geographic atrophy is something categorically different, and understanding why helps set realistic expectations for what can and cannot be managed.

Normal aging of the eye: As the eye ages, the lens stiffens (causing the need for reading glasses), the pupil gets smaller (letting in less light), the density of the lens may increase (slightly reducing contrast and color vibrancy), and the speed of dark adaptation slows. These changes are gradual, affect central and peripheral vision roughly equally, and do not create blind spots or scotomas. They explain why many older adults prefer brighter light for reading — but they do not cause the central vision loss of AMD or GA.

What AMD adds: In AMD, a specific structure at the very center of the retina — the macula, responsible for all sharp, detail-oriented vision — begins to deteriorate. Early and intermediate AMD involves the accumulation of yellowish deposits (drusen) under the retina and changes in the retinal pigment layer. Many people with early or intermediate AMD see reasonably well for years and the changes may only be detectable on an eye exam, not in daily life.

What GA adds on top of that: Geographic atrophy is what happens when AMD advances to the point where actual tissue death occurs. Patches of the macula physically die and are replaced by areas of non-functioning retina. These patches are permanent. The cells do not regenerate. As the patches grow and approach or enter the very center of the macula (the fovea), the specific activities that depend on sharp central vision — reading, recognizing faces, seeing fine detail — become increasingly difficult. This is fundamentally different from the gradual dimming and contrast loss of normal aging; it is a progressive loss of the most precise and detailed part of vision.

Why the distinction matters: People sometimes confuse GA symptoms with “just getting old” and delay seeking specialist care. The critical difference: normal aging does not create central blind spots, does not cause letters to disappear from the middle of a word, and does not create the distortion of wet AMD. If you notice these specific changes — especially if they develop over weeks rather than years — they are not normal and should be evaluated promptly. On the other hand, the peripheral vision changes and slowed dark adaptation of normal aging do coexist with GA and are not a sign that GA is getting worse; separating these helps you report accurately to your eye doctor what is changing versus what has been gradually present for years.

You may have heard that AMD “runs in families” or that certain genes raise your risk. This is true, but the practical importance of genetic testing for most people with GA is more limited than it sounds.

The genes involved: The two biggest genetic risk factors for AMD are a variant in the CFH gene (complement factor H) and variants near the ARMS2 and HTRA1 genes. Together they account for roughly half of the genetic risk for advanced AMD. These genes are involved in the complement immune system — the same system the two approved treatments (Syfovre and Izervay) target. Other complement-related genes like C3 also contribute risk.

What testing cannot do for you: For most people already diagnosed with GA, genetic testing will not change your treatment. It does not tell your doctor whether to recommend AREDS2 vitamins — that decision is the same regardless of your genes. It does not tell your doctor which injection treatment is better for you — neither drug has been proven to work better or worse based on genetics. And it does not predict how fast your own GA will grow — your actual scan results over time are a more reliable guide.

What testing can do: It is sometimes useful for ruling out other conditions that can look like GA on scans but are actually inherited retinal diseases — for example, Stargardt disease. If you developed macular atrophy at a younger age than usual, or if multiple family members have it at unusual ages, your eye doctor may test for these other genetic causes to make sure the diagnosis is right before starting treatment.

For your family: The most useful advice for first-degree relatives (children, siblings) is practical: don’t smoke, eat a Mediterranean-style diet rich in leafy greens and fish, and get regular dilated eye exams starting in their 50s. A genetic test would not change any of this advice. If you are interested in testing for personal or family reasons, ask your eye doctor whether a referral to a genetic counselor makes sense.

Knowing what to expect makes the visit much less daunting. Here is a practical guide to your first retina specialist appointment.

What to bring: A list of all your current medications, including eye drops and supplements (AREDS2 vitamins especially). Copies of recent eye scans or reports if you have them. Reading glasses. A trusted family member or friend — it is genuinely helpful to have someone with you to remember what is said. A written list of your questions, since it is easy to forget once you are in the room.

The appointment itself: Your vision will be tested on a standard eye chart and possibly through a dimming filter (which assesses the low-light vision GA often affects more than the standard chart). Your eyes will be dilated with drops; this causes blurry near vision and light sensitivity for 2–4 hours, so plan for not driving and bring sunglasses. With your pupils dilated, the specialist examines the back of your eye with a bright magnifying lens.

The scans: You will almost certainly have imaging — most commonly OCT (a painless light-based scan producing a cross-section of the retina layer by layer) and fundus autofluorescence (FAF, a photograph using specific light that makes atrophic patches show up as dark areas). Both take only a few minutes, involve no needles, no dye, and no radiation. Bringing prior scans is very valuable — comparing current to older images shows how fast or slowly your GA is growing, which is the most important piece of information for the treatment decision.

After the exam: Your specialist will review findings with you. Ask explicitly: “Can you show me my scan and explain what I am looking at?” Seeing the images yourself makes the condition much easier to understand. You will likely discuss whether treatment is appropriate, what the options are, and the monitoring plan. This is the right time to work through every question on your list.

Questions to ask your doctor

Is my AMD “dry” or has it advanced to geographic atrophy? Is it in one eye or both?
Where is the atrophy relative to the center of my vision — has it reached the fovea yet?
How fast does my GA appear to be growing, and how will you measure that over time?
Am I a candidate for one of the approved injection treatments? Why or why not?
What signs of “wet” AMD should make me call you right away?

Diagnosis & Monitoring

Diagnosing GA and tracking it over time relies mostly on painless retinal imaging done in the office. Understanding these tests helps you follow your own progress and ask better questions. None of them hurt, and most take only minutes.

The eye exam and your symptoms

Your retina specialist will check your vision on an eye chart, measure your eye pressure, and examine the macula with the pupil dilated using bright magnified lenses. Because GA can be present before it noticeably affects central vision, it is sometimes first found on a routine exam. Tell your doctor about any trouble reading, missing patches, distortion, glare, or new difficulty in low light — these everyday details often matter more than the eye-chart number alone.

You may also be given a low-luminance vision test (reading the chart through a dimming filter). People with GA often see far worse in dim light than the standard chart suggests, and this “low-luminance deficit” helps explain real-world struggles at dusk or in restaurants.

The Amsler grid — a simple home tool. An Amsler grid is a square of straight lines with a central dot. Looking at it one eye at a time (with reading glasses, covering the other eye), you check whether any lines look wavy, broken, blurry, or missing. New waviness or distortion is a classic warning sign of conversion to wet AMD and should prompt a prompt call to your eye doctor. Ask for a grid, post it somewhere you will use it daily, and learn what your “normal” looks like so you can spot a change.

The scans that map your GA

Optical coherence tomography (OCT) — a quick, light-based scan (no dye, no radiation) that produces a cross-section of the retina, like a microscopic CT. It shows the loss of the RPE and photoreceptor layers that defines atrophy, measures drusen, and detects the fluid that would signal wet AMD. OCT is usually done at most visits.
Fundus autofluorescence (FAF) — a special photograph that makes atrophic areas show up as dark patches with a bright border. FAF is the standard way to measure the size of GA and to watch it grow over months. Certain bright (hyperautofluorescent) patterns at the edges predict faster growth.
OCT angiography (OCTA) — a dye-free scan of retinal blood flow, useful for spotting the early abnormal vessels of wet AMD.
Color and near-infrared photos document the overall picture and allow careful comparison over time.

Making sense of your scan results

You do not need to be an expert, but a few ideas help you follow along:

The area of atrophy (often given in square millimeters) is what doctors track over time. A treatment “works” if that area grows more slowly than it otherwise would.
Whether the atrophy is foveal (central) or extrafoveal (off-center) strongly affects both your vision and how much there is to protect by treating.
Whether the disease is one eye or both, and how fast it has grown between visits, guides decisions.
Ask to see your FAF images side by side over time — many people find it motivating and clarifying to watch their own trend.

What the vision numbers mean

You will hear several different measures of vision, and they capture different things:

Visual acuity (e.g., 20/40, 20/200): how small a letter you can read on a chart in good light. It is useful but can look “better” than your real-world vision because GA spares the spots between letters.
Low-luminance acuity: the same chart read through a dimming filter. People with GA often do much worse here, which explains trouble at dusk or in dim rooms even when the standard number looks fair.
Contrast sensitivity: the ability to tell apart shades of gray — often reduced in GA and a big reason faces and steps become hard to see.
Reading speed and the size of your central blind spot capture day-to-day function and may be measured in low-vision evaluations.

If your eye-chart number seems better than how you actually see, you are not imagining it — ask your team about these other measures, which often track your real experience more closely.

Retina specialists use precise definitions agreed on by international expert panels (the Classification of Atrophy Meetings, or CAM). On OCT, cRORA (complete RPE and outer retinal atrophy) is established geographic atrophy; iRORA (incomplete RPE and outer retinal atrophy) is an earlier, “nascent” stage that may progress to full GA. You may see these terms in your chart or imaging report. The key point: the earlier and more precisely atrophy is identified, the sooner decisions about monitoring and treatment can be made.

Genetic risk and family screening

Several genes influence AMD risk, most notably CFH (complement factor H, e.g., the Y402H variant), ARMS2, and C3. However, genetic testing is not currently used to decide treatment, and it does not change whether you should take AREDS2 supplements. Its main value is helping explain risk and encouraging close relatives to get regular dilated eye exams. If you are interested, ask whether testing or genetic counseling makes sense for your family — but know that a normal test does not mean you are safe, and an abnormal one does not change today’s care.

How often you will be seen

People with GA are typically monitored every 6 to 12 months when not on treatment, and more often (often monthly to every other month) once injections begin. Imaging is repeated to measure growth and to catch wet-AMD conversion early. The schedule is individualized — ask your doctor what is right for you, and try not to skip visits even when your vision feels stable, because growth is often silent.

When your retina specialist describes your GA as “foveal sparing,” it is one of the most important things you can hear. Understanding what it means — and why it matters — helps you understand both your current vision and your treatment options.

What the fovea is: The fovea is the very center of the macula — a tiny pit, roughly 1.5 mm across, that is responsible for your most precise visual detail. When you look directly at something — a printed word, a face, a fine line — you are using your fovea. It has the highest concentration of cone photoreceptors (the cells responsible for sharp detail and color) in the entire retina, roughly 200,000 cones per square millimeter. Losing foveal function is what causes the most noticeable difficulty with reading and recognizing faces.

What “foveal sparing” means: GA often begins around the fovea rather than at its center. The atrophy patches develop in a ring-like pattern outside the foveal zone and grow inward and outward over time. “Foveal sparing” means that the fovea itself has not yet been destroyed by the atrophy — it sits like an island in the center of an increasingly damaged surrounding area. Many people with foveal-sparing GA have surprisingly preserved reading vision even when their overall atrophy area is large, because the single most important spot is still intact.

Why it matters for your vision timeline: Central reading vision and face recognition depend on the fovea. As long as foveal sparing is maintained, you keep the ability to read (with or without magnification aids), recognize faces, and see fine detail in your central gaze, even as the surrounding damage grows. The moment atrophy begins to eat into the fovea itself — called “foveal involvement” or loss of foveal sparing — reading and fine-detail vision become substantially harder. This is often the most significant functional transition in the natural history of GA.

Why it matters for the treatment decision: Most of the long-term benefit data for the approved drugs is strongest in people whose atrophy is not yet subfoveal (i.e., still foveal-sparing). Slowing growth before the atrophy reaches the fovea is more meaningful than slowing it after, because there is still a specific, high-value functional area to protect. If your specialist tells you that your GA is foveal-sparing with the edge of the atrophy approaching the fovea, that is often the most urgent time to discuss treatment seriously. Conversely, if the fovea is already significantly involved, the treatment calculus changes — the atrophy-slowing benefit is still present, but the central acuity impact is already underway.

Ask your doctor at every visit: “Has the atrophy moved closer to the center since last time?” and “Is my foveal sparing still intact?” These are the two most important single pieces of information for tracking your vision trajectory.

One of the most useful things your eye doctor can tell you is not just how large your atrophy is today — but how fast it is likely to grow. It turns out that the appearance of the bright border around your atrophy on the special FAF photograph predicts a lot about growth speed.

What the junctional zone is: On a fundus autofluorescence (FAF) scan, your atrophy appears as a dark patch (because the dead cells no longer glow). Around the edge of that patch, there is often a bright glowing border called the junctional zone. The pattern of that glow tells your doctor something important.

The four patterns and what they mean: Researchers have identified several distinct patterns in the junctional zone. “Diffuse-trickling” (a widespread, irregular glow with streaks toward the center) and “banded” (a thick, even ring of brightness) are associated with faster growth — studies find these lesions can grow two to three times faster per year than lesions with no bright border or a small “focal” glow. So if you hear your doctor describe your FAF pattern as “banded” or “diffuse,” that is a signal that slowing growth actively might be more urgent than it would be for a slower-growing pattern.

What the OCT scan adds: Your optical coherence tomography (OCT) scan provides a cross-section that shows a precursor zone around the main atrophy patch — called iRORA (incomplete RPE and outer retinal atrophy). This is the “expansion front” where the disease is advancing. Watching this zone over time on OCT gives your doctor an early read on where the atrophy is heading and how quickly.

What this means for you: Ask your doctor about your FAF pattern and whether your scans suggest a fast-growth or slow-growth profile. This information matters both for deciding whether and when to start treatment, and for understanding what to realistically expect. Someone with a slow-growing, non-central lesion faces a very different near-term outlook than someone with a fast-growing pattern approaching the fovea.

You can also ask to see your FAF image side by side with one from a previous visit. Watching the dark patch change — or not change much — is one of the clearest ways to understand your own disease trajectory.

If your eye doctor has ordered multiple types of scans, you may wonder why one is not enough. Each of the main scans used in GA management sees something slightly different, and together they give a more complete picture than any one alone.

OCT (optical coherence tomography) — the detailed cross-section: OCT is quick (usually under a minute), uses light rather than radiation or dye, and produces a detailed cross-section of your retina — like a microscopic MRI slice through the layers. It shows the specific layers that are damaged in GA (the RPE support layer and the overlying photoreceptors), measures individual layers, and detects the tiny pockets of fluid that would signal a switch to “wet” AMD. Because it sees structure in three dimensions, it also shows the iRORA zone — the early-warning area around the main atrophy patch. OCT is usually done at most visits because of its speed and the information it provides each time.

FAF (fundus autofluorescence) — the area photograph: FAF uses a specific wavelength of light that makes cells containing lipofuscin (a waste product) glow brightly. Atrophic cells, which no longer contain lipofuscin, show up as dark patches. FAF is the main tool for measuring the area of your atrophy patch — the number your doctor compares over time to track growth. The pattern of brightness at the edge of the dark patch (the junctional zone) is the main prognostic biomarker used in GA. FAF is typically done less often than OCT — perhaps at every other visit or every 6 months — because it is the main trend-tracking measurement.

OCTA (OCT angiography) — the dye-free blood flow map: OCTA is a newer version of OCT that detects motion (blood flowing in the vessels) rather than just structure. It produces a map of blood flow in the retina and the layer beneath it without needing any dye injection. For GA patients, OCTA is particularly useful for looking for the early signs of “wet” AMD developing — abnormal blood vessels growing into the retina. It may be done less often than OCT but more regularly if your doctor has any concern about wet AMD conversion, which can happen in a GA-affected eye.

If you are ever unsure why a particular scan is being ordered, just ask: “What are you looking for with this scan that the others don’t show?” Understanding the scans helps you understand the disease.

Questions to ask your doctor

How large is my atrophy now, and how will we know if it is growing?
How close is the atrophy to the center of my vision?
Do my scans show any features that predict faster progression?
Should I be using an Amsler grid at home, and what change should prompt a call?
Is genetic testing useful in my situation, and would it change anything?

Treatment Options

This is the section that has changed the most. Until 2023 there were no approved treatments for GA. Now there are two, plus important supportive measures. Here is what each one is, what to realistically expect, and how to think about choosing.

The honest headline. The two approved drugs slow the growth of atrophy. In the major trials they reduced how fast the GA patch expanded — they did not make existing blind spots shrink or bring back lost vision. Whether that slowing is worth the burden and risks of regular eye injections is a personal decision, and a very reasonable one to discuss in depth with your retina specialist.

Pegcetacoplan (Syfovre)

What it is: A complement C3 inhibitor, given as an injection into the eye (intravitreal), either every month or every other month. It was the first drug ever FDA-approved for GA (February 2023).

What the studies showed: In two large trials (OAKS, NCT03525613, and DERBY, NCT03525600), Syfovre slowed atrophy growth by roughly 16–21% at one year, with the effect increasing over time. In the long-term extension study (GALE, NCT04770545), five years of treatment delayed GA progression by about 1.5 years in people whose atrophy was not yet under the very center, with growth-rate reductions reported up to about 45% in later periods.

Safety you must know about: In December 2024 the FDA added a warning about retinal vasculitis and retinal vascular occlusion — a rare but potentially severe inflammation of the eye’s blood vessels that has occurred most often after the first injection and can threaten vision. In real-world registry data the rate is on the order of 1–2 per 100,000 injections, but the consequences can be serious. Other risks include eye inflammation, increased eye pressure, infection (endophthalmitis), and a small increase in conversion to wet AMD. Report sudden vision loss, pain, or redness immediately.

Avacincaptad pegol (Izervay)

What it is: A complement C5 inhibitor, given as a monthly intravitreal injection. FDA-approved in August 2023.

What the studies showed: In the GATHER1 (NCT02686658) and GATHER2 (NCT04435366) trials, Izervay reduced atrophy growth by roughly 14–19% at two years. In the open-label extension presented in 2025, the benefit kept widening — about a 40% reduction in growth from month 24 to 3.5 years compared with projected no-treatment. In February 2025 the FDA expanded the label to remove the previous limit on how long it could be dosed, giving more flexibility for long-term use.

Safety: Through 3.5 years of follow-up, Izervay showed no cases of retinal vasculitis or occlusive vasculitis and no increased eye-inflammation risk — a point many doctors weigh when comparing the two drugs. Standard injection risks (inflammation, pressure, infection, and a small wet-AMD conversion risk) still apply.

The two approved drugs at a glance

	Syfovre (pegcetacoplan)	Izervay (avacincaptad pegol)
Target in the complement cascade	C3 (earlier step)	C5 (later step)
How often it is injected	Monthly or every other month	Monthly
FDA approval	February 2023 (first ever)	August 2023; label expanded Feb 2025
Slowing of atrophy growth	~16–21% at 1 yr, more over time; ~1.5-yr delay at 5 yr (non-central GA)	~14–19% at 2 yr; ~40% by 3.5 yr
Notable safety point	FDA warning (Dec 2024) for retinal vasculitis, mostly after first injection	No vasculitis seen through 3.5 yr
Restores lost vision?	No — slows progression only	No — slows progression only

An intravitreal injection sounds frightening but is a routine, quick office procedure. Your eye is numbed with drops (and sometimes a gel or small injection of anesthetic), cleaned with an iodine solution to prevent infection, and held open gently with a small clip so you do not have to worry about blinking. The injection itself takes a second or two; most people feel pressure rather than pain. Afterward your eye may feel scratchy or look a little red for a day or two, and you may see a few floaters. You will usually be told how to watch for warning signs and when your next visit is. Many people are surprised at how manageable it becomes.

Both drugs work on the same overactive complement system and both slow GA; there is no head-to-head trial proving one is superior at preserving vision. In practice, retina specialists weigh:

Dosing burden: Syfovre can be given every other month; Izervay is monthly.
Safety profile: Syfovre carries the retinal-vasculitis warning; Izervay has not shown those cases in long-term data.
Your situation: location of the atrophy, the fellow eye, other eye conditions (such as a history of inflammation), your ability to attend frequent visits, and your own comfort with the risks.
Cost and coverage (see below).

There is no single right answer. A thoughtful conversation about your priorities is the best way to choose — and it is reasonable to decide that watchful waiting plus low-vision support is the right path, especially if the atrophy is already central.

What to expect over the first year

It helps to set realistic milestones. In the first months you should not expect your vision to improve — the aim is that it declines more slowly than it would have. Your doctor will repeat OCT and FAF imaging to compare your atrophy size over time; the benefit of treatment is usually clearest when these images are lined up over a year or more. Stay alert for warning signs (especially around the first injection), keep your appointments, and give the treatment time. If the burden becomes too much, or if your priorities change, you can revisit the decision with your doctor — this is an ongoing conversation, not a one-time commitment.

Myth: “The injections will restore my vision.” Fact: They slow further loss; they do not bring back vision already lost.
Myth: “If I feel fine, I can skip visits.” Fact: GA grows silently and wet AMD can appear suddenly; regular imaging catches changes you cannot feel.
Myth: “One drug is clearly best.” Fact: There is no head-to-head trial proving superiority; the right choice depends on your eyes, your schedule, and your tolerance for the specific risks.
Myth: “Once I start, I can never stop.” Fact: Treatment is a continuing conversation; you and your doctor can reassess based on how it is going, the burden, and your goals.
Myth: “Eye injections are unbearably painful.” Fact: The eye is numbed first; most people feel pressure, not sharp pain, and the injection itself takes seconds.

Staying safe while on treatment

If you start injections, a few habits keep you safe and get the most from therapy: learn the specific warning signs your practice gives you and keep their urgent-contact number handy; pay extra attention in the days after your first injection (when rare inflammation is most likely); keep a simple log of your injection dates and any symptoms; continue using your Amsler grid; and keep your imaging appointments even when your vision feels unchanged, because the proof of benefit is in the scans over time. If a visit shows your atrophy is growing despite treatment, that does not necessarily mean the drug failed — it may be growing more slowly than it would have — but it is worth discussing what the trend means for you.

AREDS2 supplements

The AREDS2 vitamin formula (vitamin C 500 mg, vitamin E 400 IU, lutein 10 mg, zeaxanthin 2 mg, zinc 80 mg, and copper 2 mg — without beta-carotene, which raised lung-cancer risk in smokers and former smokers) is recommended for people with intermediate AMD or GA in at least one eye. It modestly lowers the chance of progressing to advanced AMD. Two honest caveats: it is prevention, not a GA treatment (it will not shrink an existing atrophy patch), and its benefit does not depend on your genes — you do not need genetic testing to decide whether to take it. Look for a product labeled “AREDS2” and check with your doctor or pharmacist, especially if you take other supplements or blood thinners.

Things you can do yourself

Stop smoking — the single most powerful step to slow AMD; ask about cessation support.
Eat a diet rich in leafy green vegetables and fish (omega-3s); a Mediterranean-style diet is associated with slower progression.
Manage blood pressure, cholesterol, and overall cardiovascular health.
Protect your eyes from intense sunlight with UV-blocking sunglasses and a brimmed hat.
Keep every monitoring appointment, and use your Amsler grid as directed.

How GA treatment differs from wet AMD treatment

If you know someone treated for wet AMD, it helps to understand how GA care is different. Wet AMD is treated with a separate class of injections (anti-VEGF drugs) that dry up leaking vessels and can sometimes recover vision quickly; missing those injections can cause rapid loss. GA injections work differently: they slow a gradual process, do not recover vision, and are judged over many months rather than week to week. So the urgency, the goals, and the way “success” is measured are not the same. If you have both conditions at once, your retina specialist will coordinate the two treatments — this is increasingly common and manageable.

Cost and coverage

The complement-inhibitor injections are expensive — on the order of $30,000–$40,000 or more per year, per eye. Medicare and many insurers cover them, often under the medical (Part B) benefit rather than a pharmacy plan, but co-pays and prior authorization can be significant. Manufacturer patient-assistance programs and copay support exist (see Resources). Ask your retina practice’s financial counselor to check your specific coverage before starting, so there are no surprises.

When to call urgently. Whether or not you are on treatment, contact your eye doctor promptly — or seek urgent eye care — if you notice any of the following: a sudden drop or new dark patch in your vision; new or worsening eye pain; redness that does not settle; new sensitivity to light; a shower of new floaters or flashes; or new wavy/distorted lines (which can signal a switch to wet AMD). After an eye injection, these symptoms are most important in the first days to weeks and should never be “watched and waited” on. Keep your retina practice’s urgent number where you can find it.

In December 2024, the FDA updated the label for Syfovre (pegcetacoplan) to add a Warning — the most prominent type of safety notice the FDA issues — about a rare but serious risk called retinal vasculitis. If you are considering or already using Syfovre, understanding this risk helps you recognize warning signs and make a truly informed decision.

What retinal vasculitis is: Vasculitis means inflammation of blood vessels. In this case, it refers to inflammation of the blood vessels inside the eye, specifically in the retina. In the most serious cases, this inflammation can cause the blood vessels to become blocked (occlusion), cutting off blood supply to parts of the retina and potentially causing significant, permanent vision loss. A handful of the most severe cases resulted in very poor vision outcomes.

How common is it? It is rare. The best estimates from tracking systems and real-world data suggest approximately 1 to 2 cases per 100,000 injections — meaning that for any individual injection, the chance of this happening is very small. However, because many people have received Syfovre since its approval in 2023, the total number of cases in real-world use has been enough to be recognized and to prompt the FDA to require the Warning.

When is the risk highest? The large majority of reported cases happened after the first injection, with most developing within about 1 to 2 weeks of that first injection. This is why your retina specialist will often ask you to be especially vigilant after your very first Syfovre injection, and why many practices schedule a check-in visit or phone call 7–10 days after your first treatment.

Warning signs to act on immediately: After any Syfovre injection — especially in the first few weeks — go immediately to an emergency eye service (not just call the office) if you experience: sudden loss of vision or a new dark patch, new pain in the eye, significant redness, sensitivity to light, or a shower of new floaters. Do not wait to see if it improves. Time matters.

How does Izervay compare? Avacincaptad pegol (Izervay), the other approved drug, has not shown any cases of retinal vasculitis in its clinical trials through 3.5 years of follow-up. Many eye doctors now weigh this difference when helping patients choose between the two drugs. The trade-off is that Izervay requires monthly injections (Syfovre can be given every other month). Talk through this comparison with your retina specialist.

The pivotal trials that got Syfovre and Izervay approved ran for about 12 to 24 months. Since then, longer-term follow-up studies have tracked patients for up to five years — and they tell an important story about why staying on treatment matters.

The key finding: the benefit gets bigger over time. In the first year, the approved drugs reduced how fast atrophy grew by about 14–21%. But the long-term data show that gap keeps widening. It is as if both the treated eye and the untreated eye are on a slope — but the treated eye’s slope gets progressively gentler the longer you stay on treatment.

The GALE study (Syfovre, 5 years): GALE followed patients who completed the original Syfovre trials for five full years. In patients whose atrophy had not yet reached the very center (the fovea) — the group with the most to protect — five years of monthly treatment was associated with approximately a 1.5-year delay in disease progression. In plain terms: a treated patient’s atrophy at year 5 was about the same size as an untreated patient’s would have been at year 3.5. The slowing effect in years 4 and 5 was running at about 40–45% — far more than the 21% in year 1. The benefit was genuinely compounding.

The GATHER open-label extension (Izervay, 3.5 years): The long-term follow-up of the Izervay trials found a similar pattern: by years 2 through 3.5, Izervay was reducing atrophy growth by about 40% compared with what untreated patients experienced — and the February 2025 FDA label update reflected this longer-term data by removing any time limit on how long Izervay can be used.

What this means for you: If you start treatment and you “don’t feel a difference” after 6 months, that is expected — the benefit is in slower lesion growth measured on scans, not a change in how your vision feels day to day. Stopping early means giving up the compounding benefit you have been accumulating. If you and your doctor are wondering whether to continue after a year or two, the long-term data make a strong case for staying the course, especially if your atrophy is not yet central and there is still function to protect.

Syfovre and Izervay are expensive drugs — typically in the range of $30,000 to $40,000 or more per eye per year just for the medication, before the cost of office visits and imaging. The good news is that for most people in the United States, coverage and assistance programs can significantly reduce what you pay out of pocket.

Medicare coverage: Most people with GA are on Medicare. Both Syfovre and Izervay are typically covered under Medicare Part B — the medical part of Medicare, not the drug plan — because they are administered in a doctor’s office by injection. Under Part B, Medicare generally pays 80% of the approved amount after you meet your deductible, and your supplemental (Medigap) coverage, if you have it, often pays most or all of the remaining 20%. If you do not have supplemental insurance, that 20% can still be significant, and the programs below can help.

Manufacturer patient support programs: Apellis (who makes Syfovre) runs a patient support program called “Apellis Pathways.” Astellas (who makes Izervay) has “Izervay Access.” These programs provide co-pay assistance, help with prior authorization, and in some cases support for patients who cannot afford treatment even with insurance. Your retina practice’s financial counselor or patient-services coordinator can enroll you — ask specifically about this at your first treatment visit.

Independent foundations: The Patient Access Network (PAN) Foundation and The Assistance Fund are independent nonprofit organizations that sometimes have funds open for retinal diseases or AMD. These are income-based and subject to fund availability, so timing matters. Ask your practice team to check whether funds are currently open for you.

Prior authorization: Insurers typically require prior authorization before covering these drugs. Your retina practice handles this routinely, but it can take a few weeks. Make sure to start this process at least a month before you plan to begin treatment, so there is no gap. Keep a copy of your authorization approval and its expiration date.

Bottom line: Do not assume you cannot afford this treatment before talking to your practice’s financial team. They navigate this every day. Your first question to them: “What will I owe out of pocket, and what assistance am I eligible for?”

Once you start complement-inhibitor therapy, injection visits become a regular part of your life — monthly, or every other month with Syfovre. Knowing how to prepare and what to expect afterward makes the whole experience more manageable, especially in the early months.

Before the appointment: Eat and take your regular medications normally unless your doctor has told you otherwise. Arrange for someone to drive you home, because your eye will be numbed and temporarily uncomfortable, and your vision may be a bit blurry immediately after the injection. Bring a list of any new symptoms you have noticed since your last visit — changes in vision, new floaters, increased glare, or any eye discomfort. If you take blood thinners (aspirin, warfarin, newer anticoagulants), ask your doctor in advance whether you need to adjust them; for most patients they are continued without change, but it is worth confirming. Wear or bring sunglasses, as the office lighting and any dilation drops may make you light-sensitive for a few hours.

What happens in the procedure room: Your eye will be numbed with drops, and sometimes a small injection of anesthetic gel at the surface of the eye for added comfort. The skin around your eye is cleaned with a povidone-iodine solution (you may notice the orange color). A small clip (speculum) holds the eyelid open gently so you do not have to worry about blinking at the wrong moment. You will be asked to look in a specific direction. The needle is very fine, and the injection itself takes about one second. Most people describe the experience as pressure, not pain. The whole procedure is typically done in under five minutes.

In the hours after: Your eye may feel scratchy, gritty, or mildly sore, like having an eyelash in it. This usually settles within a few hours to a day. You may see small floaters or a temporary shadow — this is from the medication entering the vitreous gel of your eye and is normal. Your vision may be slightly blurry immediately after. Redness (visible on the white of the eye) from the injection site is common and looks alarming but is harmless and resolves over a day or two. Avoid rubbing the eye, swimming pools, or getting soap in the eye for the rest of the day.

Warning signs that need urgent attention: In contrast to the normal mild discomfort above, contact your doctor or go to an emergency eye service if you experience: increasing rather than improving eye pain, marked redness that is getting worse rather than better, significant vision loss, a new shower of floaters that are denser than the few specks described above, flashes of light, or any symptom that feels clearly different from prior injections. After Syfovre specifically, be especially alert to these in the first two weeks after your first injection. Keep your practice’s urgent-contact number in your phone.

The Amsler grid is a simple, paper-based test you can do at home in under a minute. For people with GA, it is one of the most important daily habits you can develop — not because it tracks your GA, but because it can catch the early warning sign of a potentially sight-threatening complication (conversion to wet AMD) while there is still time to act quickly.

What it looks like: An Amsler grid is a square sheet of paper covered in straight horizontal and vertical lines, with a single dot in the very center. You can get one from your eye doctor, print one from the American Academy of Ophthalmology’s website, or use an app version on a phone or tablet. It is about the size of an index card.

How to use it: Use it in a normally lit room. Put on your reading glasses if you use them for near vision. Cover one eye completely with your palm — not just closing it, because a covered closed eye can still see light and interfere. Hold the grid about 12–14 inches (30–35 cm) from your eye — reading distance. Look at the central dot. While keeping your gaze on the dot (do not let your eyes wander around the grid), notice the lines in your peripheral field of view. Then test the other eye. Takes about 30 seconds total.

What to look for: You are looking for new changes, not permanent ones. GA itself can cause parts of the grid to look missing, blurry, or dark — and if that has been consistent for weeks or months, it reflects your existing atrophy and is not a new emergency. What matters is a new change: lines that were straight yesterday now look wavy, bent, or distorted. New waviness or distortion is the classic warning sign of wet AMD developing — the leaking blood vessels of wet AMD literally push the retina unevenly, bending how straight lines appear. A new central dark patch or a sudden significant change in what you see is also a warning sign.

What to do if you notice a change: Call your retina specialist the same day, or go to an emergency eye service if you cannot reach your doctor. Do not wait to “see if it improves.” Wet AMD, if caught within days of onset, can often be treated aggressively with excellent outcomes. Waiting even a week can mean the difference between stopping early bleeding and dealing with established scarring.

The key is knowing your own “normal” on the grid so you notice a deviation. Use it every day, same eye, same distance, same lighting. Keep it somewhere you will actually see it — taped to the bathroom mirror or beside the coffee maker.

Questions to ask your doctor

Given where my atrophy is, am I likely to benefit from starting treatment now?
Would you recommend Syfovre or Izervay for me, and why?
What is the realistic goal — how much slowing might I expect, and over what timeframe?
What are the warning signs after an injection, and how do I reach you urgently?
What will this cost me, and is there assistance available?
If I choose not to treat, what is the plan to protect my vision and function?

class="content-section" data-stage="advanced,trials">

Advanced Therapy & Clinical Trials

The current drugs slow GA but require ongoing injections and cannot restore vision. That has spurred an unusually active pipeline aiming for two things: treatments you take less often (or even once), and treatments that might actually improve vision. None of these are approved yet, but several are in late-stage testing. Clinical trial participation may be an option — ask your retina specialist or search ClinicalTrials.gov.

A word about trials. Investigational therapies are not approved and carry unknown risks, but trials are how every approved treatment came to be. A good trial offers careful monitoring and access to leading specialists, often at no cost for the study drug. Ask whether you are eligible, what is involved, what is paid for, whether there is a chance of receiving a placebo/sham, and what happens after the study ends.

New complement drugs

Vonaprument (formerly ANX007, Annexon) — a monthly eye injection that blocks an earlier complement protein (C1q). Its pivotal Phase 3 trial, ARCHER II (NCT06510816), completed enrollment of more than 630 patients in July 2025. Notably, its main goal is preventing vision loss (loss of three lines of vision on the eye chart), not just slowing the size of the atrophy — a meaningful difference for patients, because it directly targets what people care about. Top-line results are expected in the second half of 2026.
Danicopan (AstraZeneca) — an experimental oral (pill) complement factor D inhibitor in Phase 2. If it works, a pill could spare some people from eye injections entirely.

Gene therapies — aiming for a one-time treatment

Gene therapies deliver genetic instructions that turn the eye into its own long-lasting complement “factory,” potentially from a single treatment instead of lifelong injections:

OCU410 (Ocugen) — a single under-the-retina injection of a gene-modifier therapy. In its Phase 2 ArMaDa trial (NCT06018558), early 12-month data showed about a 31% reduction in atrophy growth with no treatment-related serious adverse events; a Phase 3 registrational trial is planned to begin in late 2026.
JNJ-81201887 (Johnson & Johnson) — a single eye injection of a gene therapy that makes a protective protein (soluble CD59) to block the final, membrane-damaging step of complement. Studied in the Phase 2b PARASOL trial (NCT05811351).
CTx001 (Complement Therapeutics) — a newer gene therapy that received FDA Fast Track status; its application to begin U.S. testing was cleared in late 2025, with first dosing expected in early 2026.
SAR446597 (Sanofi) — a gene therapy with FDA Fast Track status, in early-phase testing since late 2025.

Cell therapy — replacing what was lost

Rather than slowing damage, cell therapies try to replace the dying support layer:

OpRegen / RG6501 (Lineage Cell Therapeutics with Roche/Genentech) — a one-time transplant of laboratory-grown retinal pigment epithelium cells placed under the retina, studied in the GAlette trial (NCT05626114). In early results, treated eyes with extensive coverage of the atrophy gained vision on average (about +6 to +9 letters on an eye chart over up to three years) with structural signs of retinal repair — the first hints that improvement, not just slowing, might one day be possible. This remains experimental and involves retinal surgery.
iPSC-derived RPE cell therapy (NIH) — an early U.S. trial using replacement cells made from a patient’s own reprogrammed cells, a step toward personalized retinal repair.

The U.S. registry ClinicalTrials.gov lists active studies; you can search by “geographic atrophy” and your location. Patient organizations such as the Foundation Fighting Blindness also run trial-finder services. Bring any trial you find to your retina specialist — they can tell you whether you are likely eligible and whether it is a good fit. Good questions for a study coordinator: What is the chance I receive sham/placebo? How many visits and procedures are involved? What are the known risks? Will travel or the study drug cost me anything? What happens to my care when the study ends?

What progress realistically looks like

It is easy to read about gene therapy and cell transplants and expect a cure next year. A more realistic view: the next likely milestone is a treatment that targets vision rather than only lesion size (the vonaprument Phase 3 results are expected in late 2026), and treatments that work from a single dose (the gene therapies) are progressing through mid-stage trials, with larger confirmatory studies still ahead. Cell therapies that might improve vision are the most exciting but the earliest in development. None of this changes what is available to you today — but it is genuine reason to expect more and better options in the coming years, and a reason to stay connected to a center that runs trials.

Among all the GA drugs in development, vonaprument (made by Annexon Biosciences) stands out for one specific reason: its Phase 3 trial, called ARCHER II, is testing whether the drug can prevent vision loss — not just slow the growth of the atrophy patch on a scan. That difference matters enormously for patients.

What the current approved drugs are measured on: Syfovre and Izervay were both approved because they slowed how fast the dark atrophy patch grew on a special photograph (fundus autofluorescence). That is a real benefit, but the pivotal trials were not designed to prove that the drugs protected your ability to see letters on an eye chart. Doctors believe the two things are related, and longer-term data suggest they are — but no approved GA drug has yet passed a formal test of vision preservation.

What ARCHER II is testing: The ARCHER II trial (NCT06510816) has a primary goal of showing that vonaprument prevents people from losing three or more lines of vision on an eye chart over 18 months. Losing three lines is a meaningful, real-world change in vision that people notice in daily life. If ARCHER II succeeds on this endpoint, vonaprument would become the first GA treatment proven to protect vision in a formal clinical trial — a significant milestone for the field.

How vonaprument works differently: The approved drugs block steps in the complement system called C3 (Syfovre) or C5 (Izervay). Vonaprument blocks an earlier step called C1q, which is the “trigger” for one branch of the complement system. C1q is also found on nerve cells in the retina, which is why researchers believe blocking it might help protect not just the RPE support layer but also the light-sensing cells above it.

Where the trial stands: ARCHER II finished enrolling its more than 630 patients in July 2025. Everyone who joins the trial gets a monthly eye injection (either vonaprument or a sham injection). Topline results are expected in the second half of 2026. If you are interested in this trial, note that enrollment is complete; however, if the results are positive, access to the drug may become possible through approval or compassionate use. Keep asking your retina specialist to update you as results emerge.

Of all the treatments being studied for GA, OpRegen (now called RG6501, developed jointly by Lineage Cell Therapeutics and Roche/Genentech) is the most different in concept. While every other approach tries to slow the disease or block the immune process damaging the retina, OpRegen tries to actually replace the cells that have already died.

What it is: OpRegen is a one-time surgical treatment. Retinal pigment epithelium (RPE) cells — the support layer that breaks down in GA — are grown in the laboratory from human stem cells, then injected in a liquid suspension beneath the retina during a standard eye surgery (a vitrectomy, similar to what is used for other retinal procedures). The goal is for those transplanted cells to settle into the space where the dead RPE used to be, take root, and provide support to the light-sensing photoreceptors above them that may still be alive but struggling without their foundation layer.

What the early data showed: The Phase 2a GAlette trial (NCT05626114) reported something historic: in eyes where the transplanted cells covered the atrophy patch well, patients gained an average of 6 to 9 letters on the eye chart compared to before treatment — over a follow-up period of up to about three years. For context, gaining letters on the eye chart means seeing better than you did before. In a disease that normally only moves in one direction (losing vision), even a small gain is extraordinary. The OCT scans also showed structural signs consistent with cells taking hold beneath the retina. These are early results from a small number of patients, not from a full Phase 3 trial, so caution is warranted — but the signal is genuine.

What to know realistically: This is still Phase 2 (an early trial). It involves retinal surgery, which carries its own risks (a small chance of retinal detachment, cataract worsening, and others). The transplanted cells are not your own, so a short course of immune-suppressing medication is required around the time of surgery. The trial is still enrolling patients at select centers. If you are interested, the most likely eligible patients at this stage are those with extensive GA — where the disease has already progressed significantly. Ask your retina specialist whether you might qualify and which trial site is nearest to you.

If you follow the news about GA research, you will often see phrases like “FDA Fast Track designation” or “Breakthrough Therapy designation.” These sound exciting, but it is worth understanding exactly what they mean — and what they do not mean.

FDA Fast Track designation: This is granted by the FDA to a drug that treats a serious condition and may fill an unmet medical need. Fast Track means the FDA will meet more often with the company during development, give more intensive guidance, and consider reviewing the application on a rolling basis (reviewing sections as they are submitted rather than all at once). What it does not mean: the drug is proven to work, it is safe, or that approval is coming soon. It simply means the FDA is giving the development program more attention and resources. Several GA gene therapies hold Fast Track status.

Breakthrough Therapy designation: This is a step higher — it requires preliminary clinical evidence suggesting the drug may offer a substantial improvement over existing treatments. Like Fast Track, it provides enhanced guidance and faster communication with the FDA, but it is not a guarantee of approval or a prediction of how long development will take.

Priority Review: This shortens the FDA’s review of the completed application from the standard 12 months to 6 months. It is granted for drugs that may offer a major advance in treatment. It only matters once a company has submitted a complete application, which is typically after Phase 3 trials are done.

The bottom line for your expectations: When you read that a GA drug received Fast Track designation, it means the FDA has agreed this is a serious disease with unmet need — which is already obvious. It does not mean the drug works, and it does not meaningfully shorten the 5–10 years of clinical development that most drugs require from early testing to approval. Use these designations as a signal that a program is being taken seriously, but do not let them drive expectations about your timeline for access.

The most reliable signal of a drug’s potential is its Phase 3 trial data, measured against a prespecified clinical endpoint. For GA, watch for the ARCHER II results (vonaprument, H2 2026) and Phase 3 readouts from the gene therapy programs as they emerge.

One of the biggest barriers to using the approved GA treatments is that they require eye injections every month or every other month for the rest of a patient’s life. Researchers and drug companies have been actively searching for an oral (pill) option that could work the same way. Danicopan is the furthest-along candidate.

What danicopan is: Danicopan (made by AstraZeneca, also known by the research name ALXN2040) is a tablet taken by mouth that blocks a complement-system protein called factor D. Factor D plays a role in the alternative pathway of the complement system — the same general pathway that drives GA progression. By blocking it, danicopan aims to slow complement overactivity in the retina without the need for an eye needle.

Where it is in development: Danicopan is currently in Phase 2 testing for GA. This means researchers are still working out the right dose, verifying that the drug actually reaches and affects the retina when taken by mouth, and gathering initial evidence on whether it slows atrophy growth. It has not yet been studied in the large Phase 3 trials required for FDA approval. So while the concept is promising, danicopan is still several years from being available as a standard treatment — if it ultimately succeeds.

Why an oral option would be significant: Many patients find that the injection schedule — traveling to the retina specialist once or twice a month, indefinitely — is one of the hardest parts of GA treatment. This is especially true for older patients who no longer drive, live far from a retina clinic, or have other health conditions that make frequent appointments difficult. A pill taken at home would remove that barrier entirely. If danicopan or a similar oral drug proves effective in Phase 3 trials, it could expand access to treatment for many people who currently choose not to start injections because of the logistical burden.

What it would and would not change: Even if an oral complement inhibitor works, it would still be slowing GA, not reversing it — the same limitation as the current injections. And an oral drug that acts on the complement system throughout the body raises its own questions about systemic effects that intravitreal injections avoid by staying mainly inside the eye. These are questions the Phase 2 and eventual Phase 3 studies will address.

If you are interested in oral GA therapy specifically because the injection burden is a concern, mention this to your retina specialist — they may know of relevant trials or studies you could join, and it is useful information for understanding what factors most affect your treatment decisions.

Questions to ask your doctor

Am I a candidate for any clinical trial, here or at a nearby center?
Would joining a trial affect my ability to use approved treatments later?
What is involved — visits, procedures, risks — and what does it cost me?
Given my stage, is it better to treat now with an approved drug or consider a trial?

Living Well & Low Vision

Whatever you decide about medication, low-vision rehabilitation is one of the most powerful tools for keeping your independence and quality of life. It does not treat the disease — it helps you do the things you love with the vision you have. The biggest mistake is waiting too long to start.

Start low-vision rehab early. You do not need to be legally blind to benefit. Ask for a referral to a low-vision optometrist or occupational therapist as soon as central vision begins to affect daily tasks. Early training in techniques like eccentric viewing is easier to learn while you still have more vision, and many of the tools below are covered by Medicare or available free through state services.

Tools and technology that help

Magnification: handheld and stand magnifiers, illuminated magnifiers, electronic (video) magnifiers that enlarge text on a screen, and reading telescopes for distance tasks.
Digital accessibility: built-in screen readers and text-to-speech on phones, tablets, and computers; large-font and high-contrast display settings; voice assistants for reminders and calls; and audiobooks (many libraries lend them free).
Lighting and contrast: bright, glare-free task lighting positioned over your shoulder; high-contrast tableware, cutting boards, and bold-line writing paper; contrasting tape on stair edges and light switches.
Eccentric viewing training: learning to use a healthier off-center part of the retina to “look around” the central blind spot — a skill a low-vision therapist can teach.
Everyday aids: talking watches and scales, large-button phones, needle threaders, and apps that identify currency, read labels aloud, or describe a scene.

Keeping reading and hobbies

Reading is often the function people miss most. Beyond magnifiers and electronic readers, consider audiobooks and podcasts, large-print books and newspapers, and e-readers where you control the font size and contrast. Many hobbies adapt well: large-print or tactile playing cards and games, audio-described television and films, and crafts arranged with strong lighting and contrast. The goal is not to give things up but to find a new way to do them.

Driving, home safety, and daily living

GA can affect the ability to drive safely, especially as central vision declines and in low light or glare. Be honest with yourself and your family, ask about a formal driving evaluation (often available through rehabilitation centers), and plan transportation alternatives early — rideshare, paratransit, senior transportation services, and help from family. Losing the ability to drive is one of the hardest parts of vision loss for many people; planning ahead softens the transition.

At home, small changes add up: improve and even out lighting, reduce clutter and trip hazards, use contrast (dark switch plates on light walls, colored tape on step edges), organize medications with large labels or a talking organizer, and keep frequently used items in consistent places. An occupational therapist can walk through your home and tailor these changes to you.

Emotional health and support

Losing central vision is a genuine loss, and feelings of grief, frustration, anxiety, or depression are common and valid — not a sign of weakness. Screening for depression is part of good care, so tell your team how you are coping. Counseling, peer support groups (in person or by phone), and connecting with others who have AMD can make a real difference. Many people find that, with rehabilitation and support, they regain confidence and continue the activities and relationships that matter most. Vision loss does not have to mean loss of purpose or joy.

If you are supporting someone with GA, some of the most helpful things you can do are practical: help track and get to injection and imaging appointments; assist with insurance and assistance paperwork; improve lighting and contrast at home; read mail or labels aloud when asked; and arrange transportation as driving becomes unsafe. Equally important is the emotional side — encourage independence rather than taking over tasks, listen without rushing to fix, narrate helpfully (“the step is right in front of you”) without being patronizing, and watch for signs of depression or withdrawal. Learn the warning signs that need urgent care (sudden vision change, eye pain, redness after an injection) so you can act quickly. And remember to care for yourself too; caregiver burnout is real, and support exists for you as well.

Everyday technology that makes a real difference

Mainstream devices now include powerful accessibility features at no extra cost. A few worth knowing:

Smartphone and tablet accessibility: built-in screen magnifiers, large bold text, high-contrast and dark modes, and full screen readers that speak everything on screen. Voice assistants can set reminders, make calls, read messages, and answer questions hands-free.
Reading and identifying: apps can photograph and read aloud printed mail, menus, and labels; identify currency; scan barcodes; and even describe a room or a photo. Some connect you to a live volunteer or AI helper who describes what your camera sees.
Electronic magnifiers and OCR readers: desktop and portable video magnifiers enlarge and re-color text; dedicated reading machines scan a page and read it aloud.
Around the home: talking clocks, scales, thermometers, and glucose meters; voice-controlled lights and thermostats; and large-display, high-contrast remote controls and phones.

A low-vision specialist or occupational therapist can match tools to your goals and teach you to use them — this training is often the difference between a device that helps and one that ends up in a drawer.

Practical, financial, and legal planning

A few proactive steps protect your independence and reduce stress:

Transportation plan: map out rideshare, paratransit, senior-transport, and family options before driving becomes unsafe.
Benefits and services: contact your state agency for the blind/visually impaired for free or low-cost devices, training, and vocational support; people who are legally blind may qualify for additional benefits and tax considerations.
Work and accommodations: if you are still working, reasonable workplace accommodations (screen magnification, lighting, flexible tasks) are often available; a vocational rehabilitation counselor can help.
Organize key documents while reading is easier, and set up large-print or electronic statements and bill-pay to stay on top of finances.

Staying connected and active

Isolation is one of the biggest risks of vision loss, and it is preventable. Audiobooks, podcasts, accessible video calls, talking-book libraries (many free through national programs), faith and community groups, and AMD peer-support groups all help you stay engaged. Regular physical activity — walking, chair exercises, tai chi — supports both mood and balance, which matters more when central vision is reduced. Tell the people close to you what helps (good lighting, saying who you are when you enter a room, describing what’s on the plate) so they can support you naturally.

For many people, the question of driving is the one that carries the most emotional weight in living with GA. Independence, spontaneity, and a sense of adult self-sufficiency are all wrapped up in the ability to get in a car and go where you need to go. This section is about being honest about the risks, knowing how to assess them properly, and making a transition that protects both you and others on the road.

Why GA affects driving: Driving depends heavily on central vision — the vision that GA specifically damages. Reading road signs, seeing traffic lights clearly at a distance, reading the instrument panel, and recognizing pedestrians and cyclists all require the detailed central acuity the macula provides. GA also frequently affects low-light vision and contrast sensitivity, making night driving, dawn and dusk driving, and driving in rain or glare particularly problematic. Many people with GA find that their daytime highway driving is surprisingly maintained for longer than their nighttime or city driving, because highway driving requires less rapid gaze-shifting and fine reading.

The legal standard is not the safety standard: Different states and countries have different legal vision requirements for driving. Meeting the legal minimum (often 20/40 vision in the better eye with correction) does not automatically mean you are driving safely. GA can produce contrast and low-light deficits that are not captured by the standard eye-chart test. It can create central scotomas that do not always show up on a quick office exam. The legal threshold is a floor, not a ceiling of safety.

How to get a proper driving assessment: The most reliable way to evaluate whether you should still be driving is a formal on-road driving evaluation by a certified driving rehabilitation specialist (CDRS). These evaluations, offered at many rehabilitation centers and hospitals, combine an assessment of your visual function with actual in-car observation of your performance in real traffic. Your retina specialist can refer you. Results are confidential (they are not automatically reported to the DMV) and give you a concrete, expert assessment rather than a guess.

Planning ahead before it becomes necessary: The hardest transitions are the ones that happen in crisis — an accident, a close call, or a family confrontation. Planning transportation alternatives before you need them softens this transition enormously. Identify rideshare apps you are comfortable with and practice using them now. Check whether your area has senior transportation services, paratransit (if you qualify), volunteer driver programs, or medical transport for appointments. Talk to family members or friends now about what help might look like, while the conversation is calm and forward-looking rather than reactive.

Having the conversation with your family: Family members sometimes notice driving concerns before the driver does. If someone close to you has gently raised concerns, take that seriously — they are seeing something from the outside that is easy to miss from inside the car. A non-defensive first response: “Let’s get a formal evaluation together and let the specialist weigh in.” That takes the decision out of the family dynamic and puts it where it belongs.

Central vision loss from GA is a genuine, life-altering loss, and the emotional response to it is not simply a matter of attitude or coping style. Depression and anxiety are clinically recognized complications of AMD and GA, and they are both common and undertreated. Understanding this — and knowing that help is available — is part of comprehensive GA care.

How common is depression in GA? Studies of people with age-related macular degeneration find that clinically significant depression affects roughly a quarter to a third of patients, and anxiety affects similar proportions. These rates are two to three times higher than in the general older-adult population. The loss of the ability to read, drive, recognize faces, and pursue hobbies that require central vision maps onto things that matter most to many people’s sense of self and independence. Grief, frustration, fear about the future, and a sense of diminished identity are all expected responses, not signs of weakness or mental illness.

Signs to recognize: Depression in older adults can look different from the stereotypical “sadness.” Watch for: persistent low energy or motivation; withdrawal from activities or people you previously enjoyed; difficulty concentrating or making decisions; changes in sleep (too much or too little); feelings of being a burden to others; loss of appetite; or a pervasive sense that things will not get better. Anxiety may show up as excessive worry about the next scan, persistent catastrophizing about going completely blind, avoidance of social situations because of vision difficulties, or panic around injection appointments.

Why it matters clinically (beyond wellbeing): Depression affects treatment adherence. People who are depressed are statistically less likely to keep injection appointments, less likely to use AREDS2 supplements regularly, and less likely to engage with low-vision rehabilitation. Treating depression and anxiety is therefore not separate from managing GA — it directly supports the rest of your care.

What helps: Effective options include: psychotherapy (particularly cognitive-behavioral therapy, which has strong evidence in vision loss contexts), antidepressant medications (adjusted by your primary care doctor or psychiatrist for any other conditions you have), peer support groups with others who have AMD or GA (in person or by phone through organizations like the American Macular Degeneration Foundation), and low-vision rehabilitation itself (which, by restoring functional ability, often significantly improves mood and confidence). Do not wait until depression becomes severe to seek help. Tell your primary care doctor or your eye care team how you are coping at your appointments — they should be asking, and if they are not, you can raise it yourself.

Many people picture low-vision rehabilitation as something for people who are nearly completely blind. In fact, it is most useful — and most effective — when you start it early, while you still have usable central vision. Here is a realistic picture of what the process involves.

The first appointment: A low-vision evaluation is done by a low-vision optometrist or ophthalmologist who specializes in maximizing vision function. It takes longer than a typical eye exam — usually an hour or more. The specialist will assess how much useful central vision remains, test your ability to read at different sizes and lighting levels, evaluate your contrast sensitivity, and map where your central blind spot is (if any). Based on these results, they will recommend specific tools and strategies tailored to your eyes and your daily life. This is different from a standard prescription — it is about finding the specific magnification, lighting, and visual strategies that work best for your unique situation.

What you might come away with: After a low-vision evaluation, recommendations might include: a specific strength handheld or stand magnifier; an electronic desktop magnifier for reading mail and documents at home; advice on lighting type and position (often, bright LED lighting aimed directly at the task is more helpful than general overhead lighting); high-contrast accessories like a dark cutting board or bold-line writing paper; and a referral for eccentric-viewing training.

Eccentric viewing training: This is a specific skill that can be taught by a low-vision therapist. Because GA damages the very center of the retina, trying to “look directly” at something now places it exactly in the worst part of your vision. Eccentric viewing means learning to aim your gaze slightly to one side so that the thing you want to see falls on a healthier area of the retina, not the damaged center. It takes practice, but people who learn it report it makes a real difference in reading and face recognition. The earlier you start, the easier it is to learn.

Occupational therapy at home: An occupational therapist who specializes in vision loss can visit your home and recommend practical changes: where to improve lighting, how to reduce trip hazards, how to reorganize the kitchen so frequently used items are easy to find, and how to label medications safely. Many of these changes cost very little but have a significant impact on daily safety and independence.

Coverage: Medicare typically covers low-vision evaluations and, in many cases, occupational therapy visits. State agencies for the blind and visually impaired often provide free or subsidized assistive devices and in-home training. Ask your retina specialist for a referral; it is a service they should be providing proactively, not waiting for you to ask.

Questions to ask your doctor

Can you refer me to low-vision rehabilitation and occupational therapy now?
Is it still safe for me to drive, and where can I get a formal evaluation?
What devices or technology would help most with reading and daily tasks?
Who can I talk to about the emotional side of vision loss?
Are there support groups or services for me and for my caregiver?

Support & Resources

Below are specialty centers, support organizations, financial help, a glossary, and the sources behind this guide.

Mountain West / Utah

John A. Moran Eye Center (University of Utah Health), Salt Lake City — a major academic retina center with GA expertise, advanced imaging, and clinical trials; appointments via University of Utah Health (call 801-581-2352). Researchers there study GA progression and AI-based prediction of retinal function.
Moran Eye Center Low Vision & Rehabilitation services — evaluation and adaptive-device training to maximize functional vision.
Intermountain Health ophthalmology — clinics across the Wasatch Front and greater Utah for ongoing eye care.
Utah Division of Services for the Blind and Visually Impaired — state-funded low-vision services, adaptive-technology training, and vocational rehabilitation.
VA Salt Lake City Health Care System (George E. Wahlen VA) — ophthalmology and blind-rehabilitation services for eligible veterans.

U.S. national organizations

BrightFocus Foundation — Macular Degeneration Research (brightfocus.org): plain-language education and a free helpline.
American Macular Degeneration Foundation (macular.org) and the Macular Degeneration Association (macularhope.org).
Foundation Fighting Blindness (fightingblindness.org): research updates and a clinical-trial finder.
Prevent Blindness (preventblindness.org) and the American Academy of Ophthalmology’s EyeSmart (aao.org/eye-health).
VisionAware / APH ConnectCenter (aphconnectcenter.org): practical living-with-vision-loss resources.
National Eye Institute (nei.nih.gov): trustworthy AMD information and research news.

Financial assistance

Manufacturer support: Apellis (Syfovre) and Astellas (Izervay) each run patient-support and copay-assistance programs — ask your retina practice to enroll you.
Medicare typically covers approved GA injections under the medical (Part B) benefit; verify your co-insurance and any supplemental coverage.
Foundations such as the Patient Access Network (PAN) Foundation and The Assistance Fund may help with out-of-pocket costs when funds are open.
Your retina practice usually has a financial counselor or prior-authorization team — use them; they do this every day.

International access

Pegcetacoplan (Syfovre) was approved in the European Union in September 2024, the first GA treatment available there; avacincaptad pegol received a positive European opinion in 2024 with country-by-country reimbursement decisions ongoing. Access in the UK, Canada, Australia, Japan, and elsewhere is evolving through national regulators and health-technology assessments, and neither drug is yet widely available in lower-income countries because of cost and the need for specialized injection care. AREDS2-type supplements are recommended internationally, though formulations vary; if you are outside the U.S., ask your local eye specialist what is approved and reimbursed where you live.

Apps, devices, and free libraries

Talking books and audio: the National Library Service for the Blind and Print Disabled (a free U.S. program through the Library of Congress) and commercial audiobook services provide huge catalogs of audio reading.
Identification and reading apps for smartphones can read text aloud, identify objects and currency, and connect you with sighted assistance — ask a low-vision specialist which fit your phone and needs.
Electronic magnifiers and reading machines: many are covered or available on loan through state services for the blind; try before you buy.
Accessibility settings are built into every modern phone, tablet, and computer at no cost — a rehabilitation therapist can set them up with you.

AMD (age-related macular degeneration): the broad disease; comes in dry and wet forms.
Geographic atrophy (GA): the advanced, atrophic form of dry AMD.
Macula / fovea: the central retina / its very center, responsible for sharp vision.
RPE (retinal pigment epithelium): the support layer beneath the retina that breaks down in GA.
Drusen: yellowish deposits under the retina, a hallmark of dry AMD.
Complement system: an immune cascade that is overactive in AMD; the target of the new drugs.
Intravitreal injection: a medication injection into the jelly (vitreous) of the eye.
Scotoma: a blind or dim spot in the field of vision.
OCT / FAF: the two main scans used to diagnose and monitor GA.
cRORA / iRORA: precise OCT definitions of complete vs. incomplete atrophy.
Wet (neovascular) AMD: the form with abnormal leaky vessels, treated with anti-VEGF injections.
Anti-VEGF: drugs (aflibercept, ranibizumab, faricimab, bevacizumab) used for wet AMD.
Eccentric viewing: using an off-center part of the retina to see around a central blind spot.
Low-luminance deficit: seeing much worse in dim light than a standard chart predicts.

One of the most underused resources for people with GA is connection with others going through the same experience. Research consistently shows that peer support improves mood, adherence to treatment, and overall quality of life in chronic eye conditions — and for GA specifically, staying connected also means being among the first to hear about new treatment options as they develop.

Patient organizations you should know about: The American Macular Degeneration Foundation (macular.org) runs peer-support groups and a warm phone-line staffed by volunteers who themselves have AMD. The BrightFocus Foundation (brightfocus.org/macular-degeneration) publishes plain-language updates on AMD research and clinical trials and hosts webinars featuring leading researchers. The Foundation Fighting Blindness (fightingblindness.org) funds AMD research and maintains a clinical trial finder that can connect you with open studies. All three organizations have free email newsletters that provide readable, vetted updates on research developments — signing up for these is one of the simplest things you can do to stay informed without having to sift through medical journals yourself.

Support groups: Both in-person and telephone support groups are available through many of these organizations and through hospital-based low-vision programs. Hearing how other people manage the practical challenges of GA — from how they adapt their kitchen to how they handle the emotional weight of the diagnosis — provides a kind of knowledge and reassurance that no medical appointment can fully offer. Your retina specialist or low-vision therapist can often point you to local groups. If you are not near a major city, telephone- and video-based groups work just as well and eliminate travel.

Staying informed about new treatments: The GA treatment landscape is evolving unusually fast. Checking ClinicalTrials.gov for “geographic atrophy” or “age-related macular degeneration” periodically lets you see what trials are actively enrolling near you. Patient organizations often do this work for you and notify you by email. Your retina specialist is also a key resource: at each appointment, it is perfectly appropriate to ask, “Is there anything new in GA treatment I should know about since my last visit?”

Advocacy: Participating in patient advocacy — sharing your experience with policymakers, participating in research surveys, or joining patient advisory panels for clinical trials — is both a way of contributing to the field and of staying engaged with the community working on this disease. Many clinical-trial programs actively recruit patient advisors to help design studies that ask the questions that matter most to the people they are trying to help. Organizations like the Foundation Fighting Blindness and BrightFocus can connect you with these opportunities if you are interested.

It is natural to want to do everything possible to protect your vision, which means questions about diet, vitamins, and lifestyle changes come up at almost every GA appointment. Here is an honest summary of what the science supports and what it does not.

AREDS2 supplements — the one area of solid evidence: The AREDS2 vitamin formula was tested in a large, rigorous clinical trial (the Age-Related Eye Disease Study 2) and found to reduce the chance of dry AMD advancing to a more severe stage by about 25%. The formula contains: vitamin C (500 mg), vitamin E (400 IU), lutein (10 mg), zeaxanthin (2 mg), zinc (80 mg), and copper (2 mg). There is no beta-carotene in the AREDS2 formula — an earlier version of the supplement included it, but it was removed because it increased lung-cancer risk in current and former smokers. Look for a supplement labeled “AREDS2” at your pharmacy. Important caveats: this supplement reduces the risk of progression in certain AMD stages — it is not a treatment that shrinks or reverses an atrophy patch that has already formed. And you do not need a genetic test to decide whether to take it; the benefit does not depend on your genes.

Diet: A Mediterranean-style eating pattern — emphasizing vegetables (especially dark leafy greens like kale, spinach, and collard greens), fruits, fish (particularly oily fish like salmon, sardines, and mackerel rich in omega-3 fatty acids), nuts, legumes, whole grains, and olive oil — has been associated with slower AMD progression in observational studies. Lutein and zeaxanthin from food sources (egg yolks, corn, leafy greens) are the same pigments in the AREDS2 supplement and naturally concentrate in the macula. While no diet can reverse existing GA, eating this way supports overall health and may modestly slow progression.

Smoking: Smoking is the most powerful modifiable risk factor for AMD. It roughly doubles the risk of AMD developing and substantially accelerates its progression. Stopping smoking is the single most impactful lifestyle change you can make. If you currently smoke, ask your doctor about cessation support — nicotine patches, prescription medications, and behavioral programs are all available and effective.

Sun protection: Protecting your eyes from intense ultraviolet light with UV-blocking sunglasses and a brimmed hat is a reasonable precaution. The evidence for UV light as a driver of AMD progression is weaker than for smoking, but there is no downside to UV protection.

Things to be cautious about: Many products are marketed as “eye health supplements” or cures for AMD. No supplement beyond the AREDS2 formula has been proven in a rigorous clinical trial to slow GA. Be particularly careful with products containing high-dose beta-carotene if you smoke or have smoked. Always tell your eye doctor and pharmacist about every supplement you take, as some interact with prescription medications.

Understanding what has been tried and failed for GA is genuinely useful — it helps you evaluate news about new treatments more critically, understand why the approved drugs are genuinely significant, and avoid wasting hope on approaches that have already been tested and ruled out.

Lampalizumab (Genentech/Roche) — the most prominent failure: Lampalizumab was an antibody injection that blocked a protein called complement factor D — a key part of the same complement system that Syfovre and Izervay target. In early (Phase 2) testing, lampalizumab showed very promising results: in one trial subgroup (patients with a specific genetic variant), atrophy grew about 44% more slowly in the treated group. This was exciting enough to launch two large Phase 3 trials, called SPECTRI and CHROMA, enrolling thousands of patients at sites around the world. Both trials failed in 2017: lampalizumab did not slow GA growth compared to sham. Not even a trend in the right direction. This failure was a significant setback for the field and forced researchers to reconsider basic assumptions about complement biology in GA. It also demonstrates why early-phase data — even very promising data — must be confirmed in full Phase 3 trials before drawing conclusions.

Emixustat (Acucela) — a different approach that didn’t work: Emixustat targeted the visual cycle — the chemical process by which light is converted to a nerve signal in the retina. The theory was that slowing the visual cycle would reduce the production of toxic byproducts (like A2E) that accumulate in AMD. Phase 2 results did not show consistent benefit on GA growth, and emixustat did not advance to approval.

Brimonidine intravitreal implant: Brimonidine, a drug typically used in eye drops for glaucoma, was tested in a slow-release intravitreal implant form for GA. The trials did not demonstrate sufficient benefit to support approval.

The broader lesson: These failures help explain why the approvals of Syfovre and Izervay in 2023 are genuinely meaningful. Many different approaches were tried across decades, and only complement C3 and C5 inhibition succeeded in large Phase 3 trials. They also explain why researchers are now so focused on proving that new drugs can protect vision and not just slow lesion growth on a scan — the lesson of lampalizumab was that even meaningful lesion-growth slowing in early trials does not guarantee Phase 3 success. The bar for new therapies in GA is rightly high.

If you live outside the United States, are traveling, or have family members with GA in other countries, understanding where these treatments are available — and how to access them — is important practical information.

European Union: Pegcetacoplan (Syfovre) received approval from the European Medicines Agency (EMA) in September 2024 — the first GA therapy ever approved in Europe. This was a significant milestone: for the first time, patients in EU member countries have access to a licensed treatment for geographic atrophy. However, EMA approval and national availability are not the same thing: each EU country decides independently whether to reimburse the drug through its national health system, and those decisions — based on cost-effectiveness assessments — are made at a country-by-country level and can take a year or more after EMA approval. Avacincaptad pegol (Izervay) received a positive scientific opinion from the EMA’s Committee for Medicinal Products for Human Use (CHMP) in 2024, with national reimbursement decisions still in progress across member states as of mid-2026.

United Kingdom: The UK conducts its own regulatory assessments through the MHRA (Medicines and Healthcare products Regulatory Agency) and reimbursement reviews through NICE (National Institute for Health and Care Excellence). As of mid-2026, access to complement inhibitors for GA in the UK is evolving through these processes. Check the NICE website or speak with your NHS ophthalmologist for the most current status, as these decisions move on a timeline independent of US or EU approval.

Canada: Health Canada conducts its own drug reviews, and reimbursement (coverage through provincial health plans or the federal non-insured health benefits program) is assessed separately through the Canadian Drug Agency (CDA-AMC). Access in Canada is evolving; check with your retinal specialist or contact the manufacturer directly for current status.

Australia and Japan: Access through the TGA (Therapeutic Goods Administration) in Australia and PMDA (Pharmaceuticals and Medical Devices Agency) in Japan is at various stages. Both regulatory bodies conduct independent review processes that do not automatically mirror FDA or EMA decisions. Timelines are evolving.

Lower-income countries and global access: At approximately $30,000–40,000 per year per eye, complement-inhibitor therapy for GA is realistically inaccessible in most lower- and middle-income countries, both because of cost and because the drug must be given by a retina specialist in a clinic setting. This is a major global health equity issue. AREDS2-type supplements are available internationally, though formulations vary by country; if you are outside the US, ask your local eye specialist what is approved, available, and reimbursed in your location.

If you are traveling internationally while on treatment: Discuss with your retina specialist whether your injection schedule can be maintained while traveling, and ask about referral letters and medical documentation if you need emergency eye care abroad. Syfovre and Izervay may or may not be available at your travel destination, so plan injection timing around your trips if possible rather than attempting to access the drugs overseas.

Key sources

Based on the American Academy of Ophthalmology Preferred Practice Pattern for Age-Related Macular Degeneration (2024 cycle, published February 2025); the AREDS and AREDS2 studies; the OAKS, DERBY, and GALE trials of pegcetacoplan (Apellis); the GATHER1 and GATHER2 trials and open-label extension of avacincaptad pegol (Astellas); FDA prescribing information and the December 2024 Syfovre label update and February 2025 Izervay label expansion; the CAM consensus definitions for retinal atrophy; the ARCHER II, ArMaDa, PARASOL, and GAlette pipeline programs; and ClinicalTrials.gov registry records. This guide is educational and is not a substitute for advice from your own retina specialist.

A Research Guide forGeographic Atrophy

⚡ Quick Start — If You Read Nothing Else

Understanding Geographic Atrophy

Dry AMD, geographic atrophy, and wet AMD — how they fit together

What GA does to vision

How GA tends to progress over time

How GA affects daily life

Who develops geographic atrophy

Common questions, honest answers

Questions to ask your doctor

Diagnosis & Monitoring

The eye exam and your symptoms

The scans that map your GA

Making sense of your scan results

What the vision numbers mean

Genetic risk and family screening

How often you will be seen

Questions to ask your doctor

Treatment Options

Pegcetacoplan (Syfovre)

Avacincaptad pegol (Izervay)

The two approved drugs at a glance

What to expect over the first year

Staying safe while on treatment

AREDS2 supplements

Things you can do yourself

How GA treatment differs from wet AMD treatment

Cost and coverage

Questions to ask your doctor

Advanced Therapy & Clinical Trials

New complement drugs

Gene therapies — aiming for a one-time treatment

Cell therapy — replacing what was lost

What progress realistically looks like

Questions to ask your doctor

Living Well & Low Vision

Tools and technology that help

Keeping reading and hobbies

Driving, home safety, and daily living

Emotional health and support

Everyday technology that makes a real difference

Practical, financial, and legal planning

Staying connected and active

Questions to ask your doctor

Support & Resources

Mountain West / Utah

U.S. national organizations

Financial assistance

International access

Apps, devices, and free libraries

Key sources

Geographic Atrophy, Pregnancy, and Younger Adults with Inherited AMD

Complement inhibitor treatments and pregnancy

Genetic counseling for hereditary forms of GA/AMD

Low vision services and rehabilitation in younger adults

Safety & Medication Warnings

A Research Guide for
Geographic Atrophy